扶正固本Ⅰ、Ⅱ号方结合化疗治疗肿瘤临床疗效分析

Combination of “Fuzheng Guben Formula”I,II and chemotherapy for the treatment of tumor

目的观察扶正固本Ⅰ、Ⅱ号方结合化疗治疗肿瘤的临床疗效。方法将166例肿瘤患者随机分为对照组(82例)和治疗组(84例),分别给予单纯化疗和化疗结合扶正固本Ⅰ、Ⅱ号方治疗。观察两组近期疗效(临床症状控制率、生存质量、肿瘤缓解率、血液毒性反应)和1年无进展生存期(PFS)。结果治疗组临床症状控制率为80.79%,对照组为58.33%(P<0.01);治疗组生存质量评分为(75.33±10.07)分,对照组为(68.31±8.75)分,两者有统计学差异(P<0.01);治疗组严重骨髓抑制发生率低于对照组(P<0.05);治疗组1年PFS为(8.08±3.21)月,对照组为(6.17±3.89)月,两组差异有统计学意义(P<0.01)。结论扶正固本Ⅰ、Ⅱ号方能提高肿瘤化疗的临床疗效,改善患者生存质量,延长无进展生存期。

Objective To observe the clinical efficacy of ＂Fuzheng Guben Formula＂ I, II and chemotherapy in treating tumor. Methods One hundred and sixtysix cases were randomized into control group （ n = 82 ） and treatment group （ n = 84 ）. Control group was treated by chemotherapy, and treatment group was added with ＂Fuzheng Guben Formula＂ I or II. We observed the short-term effects （control rate of clinical symptoms, QOL, remission rate of tumor, blood toxicity） and 1 year progression free survival （PFS）. Results The control rate of clinical symptom was 80.79% in the treatment group and 5g. 33% in the control group （ P 〈 0.01 ） ; the life quality score was 75.33 ± 10.07 in the treatment group and 68.31 ± 8.75 in the control group, with a statistical difference between the two groups （ P 〈 0. 01 ）. The occurrence rate of severe myelosuppression in the treatment group was lower than that of the controls （ P 〈 0. 05） ; the 1 year PFS was 8.08 ± 3.21 months in the treatment group and 6.17 ± 3.89 months in the control group （ P 〈 0. 01 ）. Conclusion ＂Fuzheng Guben Formula＂ I, II can improve the clinical efficacy in patients undergo tumor chemotherapy, improve their QOL and prolong progression free survival.